Brokers Offer Predictions for BNTC Q1 Earnings

Benitec Biopharma Limited (NASDAQ:BNTC) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Benitec Biopharma in a report released on Monday, March 2nd. HC Wainwright analyst R. Selvaraju forecasts that the biotechnology company will earn ($0.32) per share for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q2 2027 earnings at ($0.33) EPS, Q3 2027 earnings at ($0.36) EPS and Q4 2027 earnings at ($0.39) EPS.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.03).

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of Benitec Biopharma in a research note on Monday, January 12th. Wall Street Zen downgraded shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Finally, Zacks Research upgraded shares of Benitec Biopharma from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Benitec Biopharma Stock Down 2.8%

Benitec Biopharma stock opened at $10.60 on Wednesday. The firm has a fifty day moving average of $11.82 and a 200-day moving average of $13.05. Benitec Biopharma has a 52-week low of $9.85 and a 52-week high of $17.15. The firm has a market capitalization of $364.11 million, a P/E ratio of -9.30 and a beta of 0.31.

Institutional Trading of Benitec Biopharma

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its holdings in shares of Benitec Biopharma by 44.5% during the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 904 shares during the period. Schonfeld Strategic Advisors LLC increased its position in shares of Benitec Biopharma by 0.7% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 262,205 shares of the biotechnology company’s stock valued at $3,532,000 after acquiring an additional 1,786 shares during the last quarter. Barclays PLC boosted its stake in Benitec Biopharma by 9.1% in the fourth quarter. Barclays PLC now owns 23,211 shares of the biotechnology company’s stock valued at $313,000 after acquiring an additional 1,928 shares during the last quarter. Truvestments Capital LLC lifted its stake in Benitec Biopharma by 156.5% in the fourth quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,339 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in Benitec Biopharma during the 2nd quarter valued at $38,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Benitec Biopharma

In related news, Director Suvretta Capital Management, L purchased 77,387 shares of Benitec Biopharma stock in a transaction on Monday, December 29th. The shares were purchased at an average price of $13.44 per share, for a total transaction of $1,040,081.28. Following the transaction, the director owned 9,700,195 shares of the company’s stock, valued at approximately $130,370,620.80. This represents a 0.80% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders acquired 190,364 shares of company stock worth $2,442,105. 4.80% of the stock is owned by company insiders.

Trending Headlines about Benitec Biopharma

Here are the key news stories impacting Benitec Biopharma this week:

• Positive Sentiment: HC Wainwright raised several near‑term and multi‑year EPS estimates (Q3/Q4 FY2026 and FY2026/FY2027) and reiterated a “Buy” rating with a $32 price target — the firm now models slightly smaller losses, which is a positive sentiment signal for the stock. HC Wainwright note on BNTC
• Neutral Sentiment: Reported short‑interest data show “0” shares and days‑to‑cover of 0.0, which appears to be a data anomaly or reflects no meaningful reported short position — this item is unlikely to move the stock materially on its own.
• Negative Sentiment: Benitec missed most recent reported quarterly EPS (reported -$0.26 vs. -$0.23 expected), and consensus full‑year EPS remains negative (around -$1.48), keeping pressure on the share price despite analyst model tweaks. Recent earnings and stock data for BNTC

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.